Shots:

• The approval is based on P-III IMpower133 study assessing Tecentriq (atezolizumab) + CT (carboplatin and etoposide) vs CT as monothx. in 403 patients in ratio (1:1) in CT-naïve patients with ES-SCLC
• The P-III IMpower133 study results: OS (12.3 vs 10.3 mos.); PFS (5.2 vs 4.3 mos.); safety of combination therapy is consistent with the safety profile of Tecentriq
• Tecentriq is a mAb targeting PD-L1 act by blocking its interaction with PD-1 and B7.1 receptors thus leading to the activation of T cells and is an approved therapy in multiple countries across the globe including the US and EU as a monothx. or combination therapy for NSCLC and SCLC

Click here to read full press release/ article

Ref: Roche | Image: Roche